CD19 and infection: In addition, soluble immune checkpoints (sCD27, sTim-3 and sBTLA) predicted infectious complications and relapses,25 and the combination of baseline CD19+B cells with those biomarkers may be more accurate to predict severe infections and future relapses, especially in patients receiving RTX as a remission induction therapy.